Membranous glomerulonephritis diagnostic study of choice: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Membranous glomerulonephritis}} | {{Membranous glomerulonephritis}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{SAH}} | ||
== Overview == | == Overview == | ||
Revision as of 05:56, 17 July 2018
|
Membranous glomerulonephritis Microchapters |
|
Differentiating Membranous glomerulonephritis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Membranous glomerulonephritis diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Membranous glomerulonephritis diagnostic study of choice |
|
FDA on Membranous glomerulonephritis diagnostic study of choice |
|
CDC on Membranous glomerulonephritis diagnostic study of choice |
|
Membranous glomerulonephritis diagnostic study of choice in the news |
|
Blogs on Membranous glomerulonephritis diagnostic study of choice |
|
Directions to Hospitals Treating Membranous glomerulonephritis |
|
Risk calculators and risk factors for Membranous glomerulonephritis diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Ahsan Hussain, M.D.[2]
Overview
- The most efficient ans sensitive test is ANA, ds-DNA antibodies specific test that is utilized for diagnosis of membranous glomerulonephritis.
- The gold standard test for the diagnosis of biopsy.
Diagnostic Study of Choice
Gold standard/Study of choice:
- The complete blood count, urinalysis, 24 hour urine collection should be performed when:
- The patient presented with signs of proteinurea and hypertension.
- A positive [test] is detected in the patient.
- Biopsy is the gold standard test for the diagnosis of membranous glomerulonephritis.
The diagnostic study of choice for membranous glomerulonephritis are:
- chemistry panel,
- complete blood count,
- urinalysis,
- 24 hours urine collection,
- creatinine clearance,
- urine albumin,
- ANA,
- anti-doublestandard DNA,
- anti-SM,
- anti Ro/SSA,
- anti La/SSB,
- serum C3 and C4 Complement levels.
- Chest CT,
- Anti PLA2Rantibody.
Diagnostic Test:
Biopsy is confirmatory of membranous glomerulonephritis.
Sequence of Diagnostic Studies
The urinalysis and comprehensive chemistry panel should be performed when:
- The patient presented with signs of hypertension and proteinurea.
- A positive ANA, anti dsDNA is detected in the patient, to confirm the diagnosis.
Diagnostic Criteria
- There are no established criteria for the diagnosis of membranous glomerulonephritis.
References
- ↑ 1.0 1.1 Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW, Ronco P, Brenchley PE, Wetzels JF (October 2012). "Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy". J. Am. Soc. Nephrol. 23 (10): 1735–43. doi:10.1681/ASN.2012030242. PMC 3458465. PMID 22956816.
- ↑ Qin W, Beck LH, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z (June 2011). "Anti-phospholipase A2 receptor antibody in membranous nephropathy". J. Am. Soc. Nephrol. 22 (6): 1137–43. doi:10.1681/ASN.2010090967. PMC 3103733. PMID 21566055.
- ↑ Timmermans SA, Ayalon R, van Paassen P, Beck LH, van Rie H, Wirtz JJ, Verseput GH, Frenken LA, Salant DJ, Cohen Tervaert JW (December 2013). "Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy". Am. J. Kidney Dis. 62 (6): 1223–5. doi:10.1053/j.ajkd.2013.07.019. PMID 24021909.
- ↑ De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC (February 2017). "A Proposal for a Serology-Based Approach to Membranous Nephropathy". J. Am. Soc. Nephrol. 28 (2): 421–430. doi:10.1681/ASN.2016070776. PMC 5280030. PMID 27777266.